In RA, IL-6 inhibition with biologics such as tocilizumab is well established [13], and TNFα inhibitors are widely used in the treatment of moderate to severe disease, whereas in SMA, this inflammatory axis remains an emerging area of interest. This evidence concerns the gene TNF and rheumatoid arthritis.